Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | MERTK | Q12866 | 9/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | ACACA | Q13085 | 1/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.37 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 7/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 7/20 | 0.36 |
| ▸ | GAS6 | Q14393 | 7/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3961848 | 0.88 | LMNA (0.41) | MERTK | |
| SCHEMBL3963408 | 0.87 | MERTK (0.39) | MERTK | |
| SCHEMBL3963399 | 0.87 | MERTK (0.39) | MERTK | |
| SCHEMBL3964007 | 0.86 | TYRO3 (0.36) | FGFR1MERTKFLT3TYRO3GAS6 | |
| SCHEMBL3961953 | 0.85 | CCNT1 (0.39) | FGFR1MERTKSIRT5FLT3TYRO3 | |
| SCHEMBL3965646 | 0.85 | TBK1 (0.44) | FGFR1MERTKSIRT5FLT3TYRO3 | |
| SCHEMBL3966644 | 0.84 | LMNA (0.42) | MERTK | |
| Hydrochloric Acid SCHEMBL3963698 | 0.84 | AXL (0.38) | FGFR1MERTKFLT3TYRO3GAS6 | |
| SCHEMBL4209762 | 0.83 | FGFR1 (0.39) | FGFR1MERTKFLT3TYRO3GAS6 | |
| SCHEMBL3966655 | 0.83 | FGFR1 (0.39) | FGFR1MERTKFLT3TYRO3GAS6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547691-B2 | [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases | ELI LILLY AND COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080306082-A1 | [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases | ELI LILLY AND COMPANY | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306082-A1 | [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases | NFKBIA, IKBKB, IKBKG | STK17B 338/4885STK17A 416/4885FGFR1 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.